QuidelOrtho has staged a striking 47% recovery over the past month — yet short sellers are not retreating, the Street's price targets sit well below the current price, and the next earnings test is less than four weeks away.
The tension between that price surge and the analyst consensus is the central story this week. The stock closed Tuesday at $17.52, up nearly 47% over the past month, but JP Morgan — the freshest voice on the name, raising its target to $12 just yesterday — maintains an Underweight rating. That $12 target implies the stock is already 30% overvalued on one of the Street's most recent views. The mean analyst target across the coverage universe sits at $18.88, which is only marginally above the current price and carries little conviction given the trajectory of cuts. Jefferies slashed from $35 to $12.50 in early May while downgrading to Hold. Citigroup cut from $30 to $13 around the same time. UBS trimmed to $17 back in April. The direction of travel has been relentlessly lower, and the stock's rally has now pushed it past most of those revised targets rather than toward them.
Short positioning corroborates the bearish Street view, though the borrow market itself is not signalling acute stress. Short interest holds at 18.5% of free float — a genuinely elevated level — and has crept up about 3% on the week as fresh shorts lean into the rally. At 12.6 million shares, the position is near its highest level of the past six weeks. Yet availability remains comfortable at 213%, meaning there are roughly two shares available to borrow for every one already short. Cost to borrow is still just 0.57% — barely above the general collateral rate — so shorts face no meaningful carry pressure. The ORTEX short score has drifted to 67.5, a six-week high, consistent with a moderately elevated but not extreme short setup. Availability has tightened noticeably versus a month ago, when it ran above 300%, but it remains well within normal ranges. The borrow market is tightening, not squeezed.
Options positioning has shifted in a way that deserves attention. After spending most of late June near the 52-week high on the put/call ratio — which briefly touched 2.41, the most defensive reading of the past year — Tuesday's close saw the PCR drop sharply to 1.44, closer to its 20-day average of 1.58. That snap lower on a day the stock fell 3.9% is unusual. It suggests some of the defensive hedges that built up through the rally are now being unwound, rather than fresh put buyers chasing the stock lower. The z-score at -0.28 confirms the PCR has moved back to roughly neutral on a historical basis, after being significantly elevated throughout the prior week.
The valuation picture offers some structural support that helps explain why the stock found buyers in the first place. Price-to-book is running at 0.47 — a deeply discounted level — and the EV/EBITDA multiple is just 5.5x. The ORTEX stock score's value pillar has been the firmest component throughout, with price-to-book below 0.55 cited explicitly in recent scoring notes. But value alone rarely resolves bearish momentum. The earnings reaction history is a practical reminder of that: the last three prints produced next-day declines of 9.9%, 7.6%, and 11.8%, with five-day drawdowns averaging roughly 11% in each case. A small group of active managers has been building positions — Newtyn Management added 741,000 shares through April, FMR added 1.26 million — but those moves preceded the bulk of the rally and may already be reflected in the price.
With Q2 results scheduled for July 29, the week ahead is less about whether the rally has fundamental backing and more about whether the short base — still near 18.5% of float and growing modestly — finds any reason to cover before that print, or instead treats any further strength as an entry point.
See the live data behind this article on ORTEX.
Open QDEL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
